Home Brain Tumors Plain language summary for IBTA COVID-19 survey results published – IBTA

Plain language summary for IBTA COVID-19 survey results published – IBTA

Earlier this year, the IBTA announced the publication of its international survey on how COVID-19 was affecting brain tumour patients and their families during the first wave of the pandemic in the spring of this year. The survey, in seven languages, was done in collaboration with the Society for Neuro-Oncology (SNO) COVID-19 Task Force. The paper reporting the survey results was published in the journal Neuro-Oncology Advances and is freely available here.

In total, 1,989 participants completed the survey from 33 countries including 1,459 brain tumour patients and 530 caregivers.

We are now pleased to announce that we have just launched a plain language summary of the COVID-19 survey results, which highlights the key findings. This plain language summary has been produced with the agreement of the authors of the original report in Neuro-Oncology Advances and the Society for…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...

Recent Comments